225 related articles for article (PubMed ID: 35880452)
1. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S
Nat Med; 2024 Feb; 30(2):498-506. PubMed ID: 38182785
[TBL] [Abstract][Full Text] [Related]
3. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
Lemaître J; Watson S
Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
[No Abstract] [Full Text] [Related]
4. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Nemunaitis J; Bauer S; Blay JY; Choucair K; Gelderblom H; George S; Schöffski P; Mehren MV; Zalcberg J; Achour H; Ruiz-Soto R; Heinrich MC
Future Oncol; 2020 Jan; 16(1):4251-4264. PubMed ID: 31755321
[TBL] [Abstract][Full Text] [Related]
5. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T; Falkenhorst J; Schulz T; Fletcher BS; Teuber A; Krzeciesa D; Klooster I; Lundberg M; Wilson L; Lategahn J; von Mehren M; Grunewald S; Tüns AI; Wardelmann E; Sicklick JK; Brahmi M; Serrano C; Schildhaus HU; Sievers S; Treckmann J; Heinrich MC; Raut CP; Ou WB; Marino-Enriquez A; George S; Rauh D; Fletcher JA; Bauer S
J Clin Oncol; 2024 Apr; 42(12):1439-1449. PubMed ID: 38408285
[TBL] [Abstract][Full Text] [Related]
6. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
7. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
8. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
[TBL] [Abstract][Full Text] [Related]
9. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
10. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C; Bauer S
Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
[TBL] [Abstract][Full Text] [Related]
11. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
[TBL] [Abstract][Full Text] [Related]
12. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
13. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
14. Next questions for the medical treatment of gastrointestinal stromal tumor.
Italiano A
Curr Opin Oncol; 2022 Jul; 34(4):348-353. PubMed ID: 35730519
[TBL] [Abstract][Full Text] [Related]
15. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
Khosroyani HM; Klug LR; Heinrich MC
Drugs; 2023 Jan; 83(1):55-73. PubMed ID: 36607590
[TBL] [Abstract][Full Text] [Related]
16. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
[TBL] [Abstract][Full Text] [Related]
17. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
18. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
[TBL] [Abstract][Full Text] [Related]
19. Ripretinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
[TBL] [Abstract][Full Text] [Related]
20. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S; Joensuu H
Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
